Cellosaurus logo
expasy logo

Cellosaurus ZR75.1 A3 (CVCL_YX82)

[Text version]
Cell line name ZR75.1 A3
Accession CVCL_YX82
Resource Identification Initiative To cite this cell line use: ZR75.1 A3 (RRID:CVCL_YX82)
Comments Population: Caucasian.
Genetic integration: Method=Transfection/transduction; Gene=HGNC; 2594; CYP19A1.
Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
Sequence variations
  • Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
Disease Invasive breast carcinoma of no special type (NCIt: C4194)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0588 (ZR-75-1)
Sex of cell Female
Age at sampling 63Y
Category Cancer cell line
Publications

PubMed=20386540; DOI=10.1038/sj.bjc.6605641; PMCID=PMC2856013
Evans A.H., Pancholi S., Farmer I., Thornhill A., Evans D.B., Johnston S.R.D., Dowsett M., Martin L.-A.
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
Br. J. Cancer 102:1235-1243(2010)

Cross-references
Cell line databases/resources cancercelllines; CVCL_YX82
Encyclopedic resources Wikidata; Q98136621
Entry history
Entry creation12-Mar-2020
Last entry update10-Sep-2024
Version number8